[February 18, 2014]MUMBAI
(Reuters) — The U.S. Food
and Drug Administration is working with Indian regulators to enhance
the quality and safety of drugs made there, the FDA's Commissioner
Margaret Hamburg said on Tuesday.

Hamburg also urged Indian regulators to work closely
with their foreign peers.

Hamburg was speaking to reporters at the end of a visit to India
which follows FDA decisions to ban the shipment of drugs to the
United States from plants of leading Indian drugmakers including
Ranbaxy Laboratories Ltd and Wockhardt Ltd.

During a visit that started on February 10, Hamburg met the Indian
drugs regulator and health ministry officials as well as executives
of local drugmakers.